Pantoprazole Aptapharma (Pantoprazole)

Pantoprazole is a proton pump inhibitor indicated for several acid‑related disorders:

• Gastro‑oesophageal reflux disease (GERD): provides symptomatic relief and promotes healing of the esophageal lining.
• Erosive oesophagitis: accelerates ulcer healing and maintains remission.
• Zollinger‑Ellison syndrome: controls pathological gastric acid hypersecretion.
• NSAID‑induced gastric ulcer prevention: reduces risk of ulcer formation in patients requiring chronic NSAID therapy.

• Pantoprazole selectively and irreversibly binds to the H+/K+‑ATPase enzyme (the gastric proton pump) on the secretory surface of parietal cells. By inhibiting this final step of acid production, it markedly lowers gastric acidity, allowing damaged mucosa to heal and reducing reflux‑related symptoms.

Pantoprazole is generally well tolerated, but adverse reactions can occur.

Common Side Effects

• Headache: mild to moderate intensity.
• Diarrhea: usually transient.
• Nausea: occasional, may improve with food.
• Abdominal pain: mild discomfort.
• Flatulence: increased gas.
• Constipation: occasional.

Serious or Rare Side Effects

• Severe allergic reactions (anaphylaxis, angioedema).
• Clostridioides difficile‑associated colitis.
• Hypomagnesemia: low serum magnesium levels.
• Hepatic enzyme elevation.
• Stevens‑Johnson syndrome or toxic epidermal necrolysis.
• Interstitial nephritis or acute kidney injury.

When prescribing Pantoprazole, consider the following precautions:

• Renal function assessment: adjust use in severe renal impairment.
• Hepatic impairment: use with caution in patients with liver disease.
• Magnesium monitoring: check levels during prolonged therapy.
• Discontinuation: avoid abrupt stopping after long‑term use to prevent rebound acid hypersecretion.
• Elderly patients: monitor for increased sensitivity to side effects.
• Store at ambient temperature: keep in the original packaging, protect from moisture and direct sunlight.

Pantoprazole may interact with several medicines; awareness of interaction severity is essential.

Major Interactions (Avoid)

• Rilpivirine: reduced absorption leading to loss of antiviral efficacy.
• Atazanavir and other protease inhibitors: decreased plasma concentrations.
• Ketoconazole: impaired absorption due to reduced gastric acidity.

Moderate Interactions (Monitor Closely)

• Clopidogrel: reduced conversion to active metabolite, potentially lowering antiplatelet effect.
• Digoxin: increased serum levels, risk of toxicity.
• Methotrexate: decreased renal clearance, may raise systemic exposure.
• Oral contraceptives: possible reduction in hormonal efficacy.